CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-451.14	-581.6	-366.25	-153.61	-650.18	377.66
Depreciation & Amortization	18.69	19.48	19.26	19.84	24.17	17.95
Stock-Based Compensation	68.32	72.5	86.57	81.03	97.95	102.39
Other Adjustments	-20.74	72.73	-38.62	-14.05	12.47	14.11
Change in Receivables	-	25	175	-200	0.31	-0.16
Changes in Accounts Payable	-1.73	44.89	-27.28	-20.25	5.16	37.51
Changes in Unearned Revenue	0.74	-0.4	-1.95	5.79	-1.01	-0.78
Changes in Other Operating Activities	15.43	2.39	10.5	20.87	15.39	-9.71
Operating Cash Flow	-369.58	-345.01	-142.77	-260.38	-495.74	538.97
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-1.74	-0.91	-1.9	-9.47	-37.19	-81.71
Purchases of Intangible Assets	-2.47	-25	-	-2.5	-	-
Purchases of Investments	-1,563	-1,018	-1,486	-1,066	-1,418	-1,509
Proceeds from Sale of Investments	1,018	1,012	1,208	1,453	1,196	555.6
Investing Cash Flow	-548.43	-31.81	-280.48	374.65	-258.66	-1,035
Long-Term Debt Issued	600	-	-	-	-	-
Net Long-Term Debt Issued (Repaid)	600	-	-	-	-	-
Issuance of Common Stock	426.92	426.03	331.98	62.66	38.59	250.95
Net Common Stock Issued (Repurchased)	426.92	426.03	331.98	62.66	38.59	250.95
Other Financing Activities	-14.65	-	-	-	-	-
Financing Cash Flow	1,012	426.03	331.98	62.66	38.59	250.95
Foreign Exchange Rate Adjustments	-0.05	0.1	-0.02	0.07	-0.08	-0.01
Net Cash Flow	94.21	49.3	-91.29	177.01	-715.88	-245.52
Free Cash Flow	-371.33	-345.93	-144.68	-269.85	-532.93	457.27
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-2772.74%	-9855.50%	-387.72%	-72.69%	-44484.90%	49.98%
Free Cash Flow Per Share	-3.92	-3.85	-1.71	-3.41	-6.85	5.69
Levered Free Cash Flow	180.25	-516.15	-367.62	-136.83	-643.65	340.93
Unlevered Free Cash Flow	-506.57	-603.3	-472.55	-210.02	-666.3	334.96

SEC Filings: 10-K · 10-Q